PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus
Sign Up to like & getrecommendations! Published in 2021 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.mct-20-1105
Abstract: Metastatic pancreatic neuroendocrine tumors (PNET) remain an unmet clinical problem. Chronologic treatment in PNETs includes observation (watchful protocol), surgery, targeted therapy, and chemotherapy. However, increasing evidence illustrates that the outcomes of targeted therapeutic options for… read more here.
Keywords: nampt dual; pancreatic neuroendocrine; pak4 nampt; inhibition ... See more keywords
Abstract 4368: PAK4-NAMPT dual inhibition as a feasible strategy for treatment of resistant pancreatic neuroendocrine tumors
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-4368
Abstract: Our studies in pancreatic neuroendocrine tumor (pNET) cell lines demonstrate hyper-activation of the Rho GTPase effector p21 activated kinase 4 (PAK4) and the nicotinamide adenine dinucleotide (NAD) salvage pathway rate limiting enzyme nicotinamide phosphoribosyltransferase (NAMPT).… read more here.
Keywords: pak4 nampt; pancreatic neuroendocrine; kpt; pak4 ... See more keywords
PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors
Sign Up to like & getrecommendations! Published in 2019 at "Cancers"
DOI: 10.3390/cancers11121902
Abstract: Pancreatic neuroendocrine tumors (PNET) remain an unmet clinical need. In this study, we show that targeting both nicotinamide phosphoribosyltransferase (NAMPT) and p21-activated kinase 4 (PAK4) could become a synthetic lethal strategy for PNET. The expression… read more here.
Keywords: pak4 nampt; pancreatic neuroendocrine; neuroendocrine tumors; nampt dual ... See more keywords